Skip to main content

Viemed Healthcare Announces Third Quarter 2025 Earnings Conference Call Details

LAFAYETTE, LA / ACCESS Newswire / October 21, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ: VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that it will host its Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025, at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

(877) 407-6176 (US Toll-Free)

+1 (201) 689-8451 (International)

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=asCOlSnC

Following the live call, a replay will be available in the Investor Relations section of the Company's website at https://www.viemed.com.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at https://www.viemed.com.

For further information, please contact:

Investor Relations
ir@viemed.com

Trae Fitzgerald
Chief Financial Officer
Viemed Healthcare, Inc.
(337) 504-3802

SOURCE: Viemed Healthcare, Inc.



View the original press release on ACCESS Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.91
-4.20 (-2.00%)
AAPL  264.43
-0.15 (-0.06%)
AMD  198.39
-1.76 (-0.88%)
BAC  52.54
-0.52 (-0.98%)
GOOG  316.37
+1.47 (0.47%)
META  649.34
-6.32 (-0.96%)
MSFT  388.80
-8.44 (-2.12%)
NVDA  193.28
+3.46 (1.82%)
ORCL  142.26
-5.82 (-3.93%)
TSLA  402.74
-9.08 (-2.20%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.